DFFN Diffusion Pharmaceuticals Inc.

1.3
+0.01  (+1%)
Previous Close 1.29
Open 1.26
Price To Book 4.33
Market Cap 77,520,143
Shares 59,630,879
Volume 4,052,907
Short Ratio
Av. Daily Volume 9,846,145
Stock charts supplied by TradingView

NewsSee all news

  1. Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program

    First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpointsFDA recommends incorporating remdesivir, where available CHARLOTTESVILLE, Va., May 26, 2020

  2. Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  3. Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases

    CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  4. Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CHARLOTTESVILLE, Va., May 18, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  5. Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., May 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 commencement of enrolment in the randomization portion is contingent upon entering into a strategic partnership.
Trans sodium crocetinate (TSC)
Glioblastoma (GBM)
Company noted March 24, 2020 that it expects delays in enrolment due to COVID-19. Previous guidance for data release was for 2022.
Trans sodium crocetinate (TSC) - PHAST-TSC
Ischemic or hemorrhagic stroke

Latest News

  1. Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program

    First U.S. study to feature double-blinded, controlled, randomized trial design with safety and oxygenation endpointsFDA recommends incorporating remdesivir, where available CHARLOTTESVILLE, Va., May 26, 2020

  2. Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  3. Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases

    CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  4. Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    CHARLOTTESVILLE, Va., May 18, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  5. Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

    CHARLOTTESVILLE, Va., May 11, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  6. Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS

    Inclusion in FDA's Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and Eastern Europe to speed time to data readout

  7. Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19

    •  Program to focus on enhanced blood oxygenation and reduction in patient progression to Intensive Care Units •  Patient enrollment planned for both the U.S. and Eastern Europe  CHARLOTTESVILLE, Va., April 27,

  8. Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

    CHARLOTTESVILLE, Va., April 01, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  9. Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus

    CHARLOTTESVILLE, Va., March 24, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  10. Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update

    $16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 17, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN),

  11. Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer

    CHARLOTTESVILLE, Va., March 12, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  12. Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC

    CHARLOTTESVILLE, Va., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a cutting-edge biotechnology company developing new treatments for life-threatening

  13. Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

    CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us"), a cutting-edge biotechnology company developing new treatments for

  14. Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us") today announced the closing of its previously announced registered

  15. CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), please note that the pricing and figures in the first

  16. Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

    CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

  17. Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

    CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

  18. Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

    CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us") a clinical-stage biotechnology company developing new treatments

  19. Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

    CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a clinical-stage biotechnology company developing new treatments for life-threatening

  20. Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in Study CHARLOTTESVILLE, Va., Nov. 11, 2019

  21. Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving